Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-03-0278
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer
Oncology
2020English

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

Nottingham Prognostic Index Is an Applicable Prognostic Tool in Non-Metastatic Triple-Negative Breast Cancer

Asian Pacific Journal of Cancer Prevention
2019English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open
Cancer ResearchOncology
2017English

Work Productivity Activity Impairment Loss of Patients With HER2 Metastatic Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy